<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553202</url>
  </required_header>
  <id_info>
    <org_study_id>AAML05P1</org_study_id>
    <secondary_id>COG-AAML05P1</secondary_id>
    <secondary_id>NCI-2009-00321</secondary_id>
    <nct_id>NCT00553202</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia</brief_title>
  <official_title>Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that
      closely match the patient's stem cells, helps stop the growth of cancer cells. It also stops
      the patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune cells and help destroy any remaining cancer cells
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
      immune response against the body's normal cells. Giving antithymocyte globulin before
      transplant and cyclosporine, tacrolimus, and methotrexate before and after transplant may
      stop this from happening.

      PURPOSE: Natural Killer (NK) cells from the donor's bone marrow may be important in fighting
      leukemia. Bone marrow donors can be selected based on the type of NK cells they have,
      specifically the killer immunoglobulin receptor (KIR) type. This study provides information
      on KIR type from potential donors, which can be used in selecting the bone marrow donor. This
      phase II trial of unrelated donor stem cell transplant in patients with high risk AML
      (monosomy 7, -5/5q-, high FLT3-ITD AR, or refractory or relapsed AML) in which KIR typing of
      the patients and potential donors will be available to the treating transplant physician at
      the time of donor selection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To define the relationship between the status of donor NK-cell receptor and patient
           outcomes after killer immunoglobulin-like receptor-incompatible unrelated donor (URD)
           and umbilical cord blood (UCB) hematopoietic cell transplantation (HCT) in young
           patients with acute myeloid leukemia with monosomy 7, -5/5q-, high FLT3 internal tandem
           duplication allelic ratio (High-FLT3-ITD AR), or refractory or relapsed acute
           myelogenous leukemia.

        -  To correlate the relationships between factors affecting NK receptor status and clinical
           events.

        -  To assess NK-cell development after URD and UCB HCT in patients with poor prognosis AML.

        -  To evaluate NK-cell reconstitution and receptor-acquisition pattern in these patients.

      OUTLINE: This is a multicenter study.

        -  Preparative regimen: Patients receive 1 of the following regimens:

             -  Hematopoietic stem cell transplantation (SCT): Patients receive busulfan IV every 6
                hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2,
                anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and
                methylprednisolone IV on days -3 to -1.

             -  Umbilical cord blood (UCB) transplantation: Conditioning regimen, infusion
                procedures, and post-transplant immunoprophylaxis for patients with an UCB donor
                are according to institutional guidelines and standards.

        -  Allogeneic hematopoietic stem cell transplantation (SCT) or umbilical cord blood (UCB)
           transplant: Patients undergo allogeneic SCT or UCB transplant on day 0.

        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive cyclosporine or tacrolimus IV
           or orally beginning on day -2 and continuing until day 50, followed by a taper until
           week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

      Blood samples will be collected periodically from both patients and donors for studies of
      natural killer cells in support of the study objectives.

      After completion of study treatment, patients are followed every 6 months for 2 years and
      then annually for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 5 years from HSCT date</time_frame>
    <description>OS - Time from HSCT until death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Incidence of NK Cell Reconstitution</measure>
    <time_frame>At 5 years from HSCT date</time_frame>
    <description>Cumulative incidence of successful reconstitution to donor level is calculated.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>From the date of SCT to the date of relapse, the date of death, or the date of last follow-up, whichever occurs first</time_frame>
    <description>The cumulative incidence of relapse or death after SCT will be calculated by considering relapse and death due to other causes as competing events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute and Chronic Graft-versus-host Disease</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Acute and chronic GVHD will be summarized.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to the Donor-specific NK-cell Receptor Expression</measure>
    <time_frame>Up to 42 days after SCT</time_frame>
    <description>The presence of donor cells is demonstrated by the detection of informative variable-number tandem-repeat polymorphisms or by fluorescent in situ hybridization with a Y-chromosome-specific probe in cases of sex-mismatched transplants. Independent variables that will be examined include donor-recipient KIR mismatch, taking into consideration the interactions with donor-recipient human leukocyte antigen (HLA) compatibility, and the numbers of CD34+ cells and CD3+ cells in the graft.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.
Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.
Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>Rabbit ATG</other_name>
    <other_name>RATG-Rabbit</other_name>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Thymoglobulin</other_name>
    <other_name>NSC #720095</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>NSC #750</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>NSC #26271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>CYA</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>Neoral</other_name>
    <other_name>Gengraf</other_name>
    <other_name>NSC #290193</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>amethopterin</other_name>
    <other_name>NSC #000740</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>Solu-Medrol</other_name>
    <other_name>A-Methapred</other_name>
    <other_name>Medrol</other_name>
    <other_name>NSC #19987</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Prograf</other_name>
    <other_name>NSC #717865</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>allogeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
    <other_name>bone marrow therapy</other_name>
    <other_name>allogeneic</other_name>
    <other_name>allogenic</other_name>
    <other_name>transplantation</other_name>
    <other_name>allogeneic bone marrow</other_name>
    <other_name>allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic SCT</description>
    <arm_group_label>Treatment (chemotherapy and allogeneic SCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Patients with primary refractory acute myeloid leukemia (AML), defined as ≥ 5%
                  bone marrow blasts after two induction courses of chemotherapy

               -  Primary refractory AML, defined as ≥ 5% bone marrow blasts after two induction
                  courses of chemotherapy

               -  AML or myelodysplastic syndrome with -5/5q- or monosomy 7 without
                  inv(16)/t(16;16) or t(8;21) cytogenetics or NPM or CEBPα mutations

               -  Relapsed AML (≥ 5% bone marrow blasts) who meet the customary WHO criteria for
                  AML

               -  AML and high FLT3 internal tandem duplication allelic ratio (high FLT3-ITD AR),
                  defined as &gt; 0.4

               -  All cases of therapy-related AML (therapy-related AML is considered high risk)

               -  Patients with AML, without inv(16)/t(16;16) or t(8;21), monosomy 7, -5/5q-, NPM,
                  or CEPBα mutations, or high FLT3-ITD AR, but with evidence of residual AML (≥
                  0.1%) at the end of Induction I; or if a minimal residual disease (MRD) is not
                  performed, then with &gt; 15% bone marrow blasts by morphology after one induction
                  course of chemotherapy

                    -  Any flow-based MRD is eligible for AAML05P1 for patients not on AAML1031,
                       whereas patients on AAML1031 must utilize the central lab as per the
                       AAML1031 protocol guidelines

          -  No Fanconi anemia

          -  Recipients of unrelated marrow or cord blood are eligible for this study

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) (for patients over 16 years of age) or Lansky PS
             (for patients 16 and under) 50-100%

          -  Total bilirubin ≤ 2 mg/dL

          -  SGOT (AST) or SGPT (ALT) ≤ 2.5 times upper limit of normal

          -  DLCO ≥ 50% OR a normal chest x-ray and pulse oximetry in patients who are unable to
             undergo pulmonary function tests

          -  Shortening fraction ≥ 27% by ECHO

          -  Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min OR
             creatinine adjusted according to age

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Patients with proven or suspected bacterial sepsis, pneumonia, or meningitis are
             eligible provided appropriate therapeutic measures have been initiated to control the
             presumed or proven infection, and systemic signs are not life-threatening

          -  No evidence or presence of a fungal infection within the past 30 days

        PRIOR CONCURRENT THERAPY:

          -  Prior chemotherapy, radiotherapy or any antileukemic therapy allowed provided patients
             meet 1 of the following criteria:

               -  Received initial treatment for relapsed AML

               -  Patients with primary induction failure or relapse who have already received
                  initial therapy and who may have gone on to have additional therapy prior to
                  receiving protocol stipulated therapy on AAML05P1

          -  No treatment for fungal infection within the past 30 days

          -  Concurrent radiotherapy to localized painful lesions allowed

          -  No other concurrent cancer chemotherapy or immunomodulating agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella M. Davies, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonathan Jaques Children's Cancer Center at Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93638-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Care of Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley's Children Cancer Center at Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3993</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Monosomy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
          <description>All patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No donor identified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fails to meet organ function</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
          <description>All Patients</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3215.34" spread="2240.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS - Time from HSCT until death</description>
        <time_frame>At 5 years from HSCT date</time_frame>
        <population>Patients without completion of planned therapy (n=68) are excluded from analyses of OS</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
            <description>All Patients</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS - Time from HSCT until death</description>
          <population>Patients without completion of planned therapy (n=68) are excluded from analyses of OS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="33.7" upper_limit="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence of NK Cell Reconstitution</title>
        <description>Cumulative incidence of successful reconstitution to donor level is calculated.</description>
        <time_frame>At 5 years from HSCT date</time_frame>
        <population>Patients without completion of planned therapy (n=68) or without NK cell status (n=38) are excluded from analyses of TExp</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
            <description>All Patients</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of NK Cell Reconstitution</title>
          <description>Cumulative incidence of successful reconstitution to donor level is calculated.</description>
          <population>Patients without completion of planned therapy (n=68) or without NK cell status (n=38) are excluded from analyses of TExp</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" lower_limit="33.8" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Disease-free Survival</title>
        <description>The cumulative incidence of relapse or death after SCT will be calculated by considering relapse and death due to other causes as competing events.</description>
        <time_frame>From the date of SCT to the date of relapse, the date of death, or the date of last follow-up, whichever occurs first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>The cumulative incidence of relapse or death after SCT will be calculated by considering relapse and death due to other causes as competing events.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute and Chronic Graft-versus-host Disease</title>
        <description>Acute and chronic GVHD will be summarized.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Acute and Chronic Graft-versus-host Disease</title>
          <description>Acute and chronic GVHD will be summarized.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to the Donor-specific NK-cell Receptor Expression</title>
        <description>The presence of donor cells is demonstrated by the detection of informative variable-number tandem-repeat polymorphisms or by fluorescent in situ hybridization with a Y-chromosome-specific probe in cases of sex-mismatched transplants. Independent variables that will be examined include donor-recipient KIR mismatch, taking into consideration the interactions with donor-recipient human leukocyte antigen (HLA) compatibility, and the numbers of CD34+ cells and CD3+ cells in the graft.</description>
        <time_frame>Up to 42 days after SCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy and Allogeneic SCT)</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Donor-specific NK-cell Receptor Expression</title>
          <description>The presence of donor cells is demonstrated by the detection of informative variable-number tandem-repeat polymorphisms or by fluorescent in situ hybridization with a Y-chromosome-specific probe in cases of sex-mismatched transplants. Independent variables that will be examined include donor-recipient KIR mismatch, taking into consideration the interactions with donor-recipient human leukocyte antigen (HLA) compatibility, and the numbers of CD34+ cells and CD3+ cells in the graft.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>All patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pharyngeal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

